Intravenous immunoglobulin as adjuvant therapy for COVID-19: A case report and literature review

Severe acute respiratory syndrome coronavirus 2 has infected and caused the death of an alarming number of individuals worldwide. No specific treatment has been internationally standardized for coronavirus disease 2019 (COVID-19); however, in some cases, intravenous immunoglobulin (IVIG) has been us...

Descripción completa

Detalles Bibliográficos
Autores principales: Flores-Oria, Carlos A, Saturno, Emilio, Ramanathan, Supriya, Martinez Castillo, Diana J, Kumar, Roshni, Ferrer, Nelson, Mossaad, Afnan, Tellez, Maria E, Jon, Cindy, Waters, Sara C, Mosquera, Ricardo A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252403/
https://www.ncbi.nlm.nih.gov/pubmed/34262773
http://dx.doi.org/10.1177/2050313X211029699
Descripción
Sumario:Severe acute respiratory syndrome coronavirus 2 has infected and caused the death of an alarming number of individuals worldwide. No specific treatment has been internationally standardized for coronavirus disease 2019 (COVID-19); however, in some cases, intravenous immunoglobulin (IVIG) has been used as adjuvant treatment in critically ill patients with COVID-19 pneumonia. We report a case of a 50-year-old man with severe COVID-19 pneumonia who received 5 days course of IVIG as adjuvant therapy. Invasive respiratory support was avoided. The patient had a successful recovery and was discharged without supplemental oxygen. A high dose of IVIG may improve survival in patients with severe COVID-19 pneumonia. In the current report, we reviewed literature on how IVIG use may improve the early stages of the disease.

Ejemplares similares